<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ELESTRIN- estradiol gel </strong><br>Jazz Pharmaceuticals Commercial Corp.<br></p></div>
<h1>ELESTRIN<span class="Sup">®</span><br>(estradiol gel)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea148a02-54c7-4a75-944b-409d6fa936a5"></a><a name="section-1"></a><p></p>
<p class="First">R<span class="Sub">x</span> Only</p>
</div>
<div class="Warning">
<a name="id_6d88b72a-e877-4ec9-9205-6280d6b79429"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Emphasis">ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER</span></p>
<p>Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no evidence that the use of "natural" estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (See <span class="Bold"><a href="#i4i_section_id_fd9f3d65-ad23-4e0e-b9f9-d84e3761df76">WARNINGS, Malignant neoplasms, Endometrial cancer</a></span>.)</p>
<p><span class="Emphasis">CARDIOVASCULAR AND OTHER RISKS</span></p>
<p>Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a></span> and <span class="Bold"><a href="#i4i_section_id_1a486a0f-5c4b-4ac3-aa40-512c2cc1d0d0">WARNINGS, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></a></span>, and <span class="Bold"><a href="#i4i_section_id_f5986d17-0edb-474d-b355-62581873c0ff"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span>.)</p>
<p>The Women's Health Initiative (WHI) estrogen alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) in postmenopausal women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively, of treatment with oral conjugated estrogens (CE 0.625 mg) per day relative to placebo. (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a></span> and <span class="Bold"><a href="#i4i_section_id_1a486a0f-5c4b-4ac3-aa40-512c2cc1d0d0">WARNINGS, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></a></span>.)</p>
<p>The estrogen plus progestin WHI substudy reported increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, invasive breast cancer, pulmonary emboli, and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) per day relative to placebo. (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a></span> and <span class="Bold"><a href="#i4i_section_id_1a486a0f-5c4b-4ac3-aa40-512c2cc1d0d0">WARNINGS, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></a></span> and <span class="Bold"><a href="#i4i_section_id_965bfadd-dafd-4313-a958-a3a0d2f4b24f">Malignant neoplasms, Breast cancer</a></span>.)</p>
<p>The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI study, reported increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 5.2 years of treatment with CE 0.625 mg alone and during 4 years of treatment with CE 0.625 mg combined with MPA 2.5 mg relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a></span> and <span class="Bold"><a href="#i4i_section_id_f5986d17-0edb-474d-b355-62581873c0ff">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span> and <span class="Bold"><a href="#i4i_geriatric_use_id_ec4c1dd0-e133-40dd-a6b9-2e707fb97c6a">PRECAUTIONS, Geriatric Use</a></span>.)</p>
<p>Other doses of conjugated equine estrogens with medroxyprogesterone acetate and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_cb9f807a-a212-4414-93ee-23bf9d130355"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Elestrin<span class="Sup">®</span> (estradiol gel) contains 0.06% estradiol in a hydroalcoholic gel base. The gel is applied onto the skin in a thin layer. The recommended area of application is the upper arm to shoulder (approximately 320 cm<span class="Sup">2</span>). One pump actuation delivers Elestrin<span class="Sup">®</span> in a unit dose of 0.87 g, which contains 0.52 mg of estradiol. The 0.87 g dose provides systemic delivery of 0.0125 mg of estradiol daily. The 1.7 g dose, two pump actuations, provides systemic delivery of 0.0375 mg daily.</p>
<p>Estradiol is a white crystalline powder, chemically described as estra-1,3,5(10)-triene-3,17-diol, (17β)-. It has a molecular formula of C<span class="Sub">18</span>H<span class="Sub">24</span>O<span class="Sub">2</span>•½H<span class="Sub">2</span>O and molecular weight of 281.4.</p>
<p>The structural formula is:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e1a3641-25ca-41bd-a940-51ae0ec64ed9&amp;name=f3f8fca9-1981-471d-89f5-6b7fbb8f49d6-01.jpg"></div>
<p>The active component of Elestrin<span class="Sup">®</span> is estradiol. The remaining components of the gel (ethanol, propylene glycol, diethylene glycol monoethyl ether, carbomer 940, triethanolamine, edetate disodium, and purified water) are pharmacologically inactive.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_aff720b6-67f5-45eb-b281-b71bb837f7ae"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.</p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.</p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.</p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_8ca63de1-f556-425c-a402-45d1bb837266"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_873f3997-0878-48a7-8d9f-f680687c8ba3"></a><a name="section-3.1.1"></a><p></p>
<h3>A. Absorption</h3>
<p class="First">Steady-state serum concentrations of estradiol are achieved in approximately 3 days following daily application of Elestrin<span class="Sup">®</span> to the upper arm.</p>
<p>Pharmacokinetic parameters for estradiol on Day 14 following daily application of 0.87 g or 1.7 g of Elestrin<span class="Sup">®</span> are summarized in <span class="Bold"><a href="#id_b081c5da-fb6b-407b-9765-46be21b658ce">Table 1</a></span>. The nominal mean delivery rates of estradiol using the baseline-adjusted average serum concentrations from pharmacokinetic studies using 0.87 g/day and 1.7 g/day are 0.012 mg/day and 0.041 mg/day, respectively.</p>
<a name="id_b081c5da-fb6b-407b-9765-46be21b658ce"></a><table border="1">
<caption><span>TABLE 1 - Summary of Unadjusted PK Parameters for Estradiol after 14 Days of Dosing</span></caption>
<col width="216px">
<col width="192px">
<col width="168px">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">  </span><span class="Bold">Pharmacokinetic <br>Parameter </span><span class="Bold"> </span>
</td>
<td class="Rrule" align="center" valign="bottom">
<span class="Bold">0.87 g Elestrin<span class="Sup">®</span><br></span><span class="Bold">(0.52 mg/d Estradiol)<br></span><span class="Bold">Mean</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">1.7 g Elestrin<span class="Sup">®</span><br></span><span class="Bold">(1.04 mg/d Estradiol)<br></span><span class="Bold">Mean</span>
</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><p class="First"><span class="Sup">a</span> T<span class="Sub">max</span> shown as median (range)</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">AUC<span class="Sub">0-24</span> (pg'hr/mL)</td>
<td class="Botrule Rrule" align="center" valign="top">335.2</td>
<td class="Botrule Rrule" align="center" valign="top">940.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">C<span class="Sub">max</span> (pg/mL)</td>
<td class="Botrule Rrule" align="center" valign="top">21.6</td>
<td class="Botrule Rrule" align="center" valign="top">66.7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">C<span class="Sub">ave</span> (pg/mL)</td>
<td class="Botrule Rrule" align="center" valign="top">15.4</td>
<td class="Botrule Rrule" align="center" valign="top">39.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">C<span class="Sub">min</span> (pg/mL)</td>
<td class="Botrule Rrule" align="center" valign="top">9.4</td>
<td class="Botrule Rrule" align="center" valign="top">21.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">T<span class="Sub">max</span> (h)<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">18 (1 – 20)</td>
<td class="Botrule Rrule" align="center" valign="top">4 (1 – 20)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Fluctuation Index</td>
<td class="Botrule Rrule" align="center" valign="top">0.80</td>
<td class="Botrule Rrule" align="center" valign="top">1.16</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">E<span class="Sub">2</span>:E<span class="Sub">1</span> ratio</td>
<td class="Botrule Rrule" align="center" valign="top">0.53</td>
<td class="Botrule Rrule" align="center" valign="top">0.98</td>
</tr>
</tbody>
</table>
<p>Mean concentrations of estradiol over a 24-hour period on Day 14 are shown in Figure 1.</p>
<div class="Figure"><img alt="Figure 1 -- Mean Concentrations of Estradiol over 24-hour Period on Day 14" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e1a3641-25ca-41bd-a940-51ae0ec64ed9&amp;name=f3f8fca9-1981-471d-89f5-6b7fbb8f49d6-02.jpg"></div>
<p>Application of sunscreen 10 minutes before application of Elestrin<span class="Sup">®</span> increased the exposure to estradiol by approximately 55%. No significant change in estradiol exposure was observed when sunscreen was applied 25 minutes after application of Elestrin. In the same study, prolonged (7 days) concomitant application of sunscreen to the site of Elestrin<span class="Sup">®</span> application increased exposure to estradiol by about 2-fold, regardless of whether it was applied before or after application of Elestrin<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a172130-9278-48e8-9a1f-6062e49cfa56"></a><a name="section-3.1.2"></a><p></p>
<h3>B. Distribution</h3>
<p class="First">The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in blood largely bound to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) and albumin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_edc8a34a-5a9f-48d4-b5cd-54bc88f280c1"></a><a name="section-3.1.3"></a><p></p>
<h3>C. Metabolism</h3>
<p class="First">Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption.</p>
<p>In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e632a1c0-999c-441c-aef5-ef2988d8f550"></a><a name="section-3.1.4"></a><p></p>
<h3>D. Excretion</h3>
<p class="First">Estradiol, estrone and estriol are excreted in the urine along with glucuronide and sulfate conjugates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ce82c7fc-b496-4067-a926-8f617d59c509"></a><a name="section-3.1.5"></a><p></p>
<h3>E. Special Populations</h3>
<p class="First">Elestrin<span class="Sup">®</span> has been studied only in postmenopausal women. No pharmacokinetic studies were conducted in special populations, including patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or any other special populations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_92a28227-6e7d-401d-97a4-55572fa54f2a"></a><a name="section-3.1.6"></a><p></p>
<h3>F. Drug Interactions</h3>
<p class="First"><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4, such as St. John's Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4, such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, and grapefruit juice, may increase plasma concentrations of estrogens and result in side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_59f7542f-7f30-48b7-9180-7528174693eb"></a><a name="section-3.1.7"></a><p></p>
<h3>G. Estradiol Transfer</h3>
<p class="First">The potential for estradiol transfer between treated postmenopausal female subjects and their untreated male partners was evaluated. Two and 8 hours after women applied 2.6 g Elestrin<span class="Sup">®</span> to one arm (12 women per time point), they engaged in direct arm-to-arm contact with a male partner for 5 minutes. No significant changes in estradiol pharmacokinetic parameters were observed in the male partners after contact.</p>
<p>Less than 10% of the estradiol dose was measured on the skin at 2 and 8 hours after application. After washing the application site with soap and water at 8 hours after application, about 1% of the dose of estradiol was measurable.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b2e4c37-1741-4fe7-abd8-ec5020fb9197"></a><a name="section-4.1"></a><p></p>
<h2>Effects On Vasomotor Symptoms</h2>
<p class="First">A randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy of 12-week treatment with three different daily doses of Elestrin<span class="Sup">®</span> for the treatment of vasomotor symptoms in 484 postmenopausal women between 28 and 74 years of age (mean 54 years; 83-88% Caucasian per group) who had at least 60 moderate-to-severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> per week at baseline. Subjects applied placebo, Elestrin<span class="Sup">®</span> 0.87 g (0.52 mg estradiol), 1.7 g (1.04 mg estradiol), or 2.6 g (1.56 mg estradiol) once daily to the upper arm. Reduction in both the frequency and severity of moderate-to-severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> was statistically significant for the Elestrin<span class="Sup">®</span> 1.7 g/day dose compared to placebo at week 4. Statistically significant reductions in both the frequency and severity of moderate-to-severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> when compared to placebo were delayed for the Elestrin<span class="Sup">®</span> 0.87 g/day dose to week 5. Both the 0.87 g/day and 1.7 g/day doses were statistically significant compared to placebo at week 12. The reductions in frequency and severity are shown in <span class="Bold"><a href="#id_4d6f4469-20f8-42a1-b5fe-b8db4b080a67">Table 2</a></span>.</p>
<a name="id_4d6f4469-20f8-42a1-b5fe-b8db4b080a67"></a><table border="1">
<caption><span>TABLE 2 - Mean Change From Baseline<span class="Sup">a</span> in the Number and Severity of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span> after Elestrin<span class="Sup">®</span> Treatment</span></caption>
<col width="96px">
<col width="108px">
<col width="132px">
<col width="144px">
<col width="132px">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><span class="Bold">Evaluation</span></td>
<td class="Rrule" align="center" valign="bottom">Placebo<br>(N=137)</td>
<td class="Rrule" align="center" valign="bottom">Elestrin<span class="Sup">®</span><br>0.87 g/day <br>(N=136)</td>
<td class="Botrule Rrule" align="center" valign="bottom">Elestrin<span class="Sup">®</span><br>1.7 g/day <br>(N=142)</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top">
<p class="First"><span class="Sup">a</span> Differences from baseline based on LS means derived from the ANCOVA model with factors for baseline, treatment, site, and treatment-by-baseline interaction.</p>
<p><span class="Sup">b</span> Unadjusted means and standard deviations, based on the first 14 days of the Screening Period.</p>
<p><span class="Sup">c</span> Severity score: 1=mild, 2=moderate, 3=severe.</p>
<p>SD: standard deviation </p>
<p>#P= ns, *P&lt;0.01, **P&lt;0.001, ***P&lt;0.0001 for treatment comparison with placebo (Dunnett's test). </p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Number of Daily <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">Baseline (Mean ± SD)<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">13.5 ± 4.5</td>
<td class="Botrule Rrule" align="center" valign="top">13.3± 4.6</td>
<td class="Botrule Rrule" align="center" valign="top">13.1 ± 6.5</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">  Mean Change: </td>
<td class="Botrule Rrule" align="left" valign="top">Week 4</td>
<td class="Botrule Rrule" align="center" valign="top">-5.1</td>
<td class="Botrule Rrule" align="center" valign="top">-6.5<span class="Sup">#</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">-8.0***</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"> </td>
<td class="Botrule Rrule" align="left" valign="top">Week 5</td>
<td class="Botrule Rrule" align="center" valign="top">-5.1</td>
<td class="Botrule Rrule" align="center" valign="top">-7.5*</td>
<td class="Botrule Rrule" align="center" valign="top">-8.8***</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"> </td>
<td class="Botrule Rrule" align="left" valign="top">Week 12</td>
<td class="Botrule Rrule" align="center" valign="top">-5.4</td>
<td class="Botrule Rrule" align="center" valign="top">-8.5***</td>
<td class="Botrule Rrule" align="center" valign="top">-10.0***</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Daily <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flush</span> Severity<span class="Sup">c</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">  Baseline (Mean ± SD)<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2.4 ± 0.3</td>
<td class="Botrule Rrule" align="center" valign="top">2.4 ± 0.3</td>
<td class="Botrule Rrule" align="center" valign="top">2.4 ± 0.3</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">  Mean Change: </td>
<td class="Botrule Rrule" align="left" valign="top">Week 4</td>
<td class="Botrule Rrule" align="center" valign="top">-0.2</td>
<td class="Botrule Rrule" align="center" valign="top">-0.5<span class="Sup">#</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">-0.7***</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"> </td>
<td class="Botrule Rrule" align="left" valign="top">Week 5</td>
<td class="Botrule Rrule" align="center" valign="top">-0.2</td>
<td class="Botrule Rrule" align="center" valign="top">-0.5*</td>
<td class="Botrule Rrule" align="center" valign="top">-0.8***</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top"> </td>
<td class="Botrule Rrule" align="left" valign="top">Week 12</td>
<td class="Botrule Rrule" align="center" valign="top">-0.3</td>
<td class="Botrule Rrule" align="center" valign="top">-0.8***</td>
<td class="Botrule Rrule" align="center" valign="top">-1.2***</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3bc227d-2205-471f-9dcd-0cd3fd12117d"></a><a name="section-4.2"></a><p></p>
<h2>Women's Health Initiative Studies</h2>
<p class="First">The Women's Health Initiative (WHI) enrolled approximately 27,000 predominantly healthy postmenopausal women to assess the risks and benefits of either the use of oral conjugated estrogens (CE 0.625 mg) alone per day or in combination with medroxyprogesterone acetate (MPA 2.5 mg) per day compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease (CHD) (nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as the primary adverse outcome studied. A "global index" included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), endometrial cancer (only in the estrogen plus progestin substudy), colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other cause. The study did not evaluate the effects of CE or CE/MPA on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</p>
<p>The estrogen alone substudy was stopped early because an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed. Results of the estrogen alone substudy, which included 10,739 women (average age of 63 years, range 50 to 79; 75.3% White, 15.1% Black, 6.1% Hispanic, 3.6% Other), after an average follow-up of 6.8 years are presented in <span class="Bold"><a href="#id_7c4d558a-6a15-4708-8b16-aa6363e30812">Table 3</a></span>.</p>
<a name="id_7c4d558a-6a15-4708-8b16-aa6363e30812"></a><table border="1">
<caption><span>TABLE 3 - RELATIVE AND ABSOLUTE RISK SEEN IN THE ESTROGEN-ALONE SUBSTUDY OF WHI<span class="Sup">a</span></span></caption>
<col width="173px">
<col width="173px">
<col width="173px">
<col width="173px">
<thead>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><span class="Bold">Event</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom">
<span class="Bold">Relative Risk</span><br><span class="Bold">CE vs. Placebo</span><br><span class="Bold">(95% nCI<span class="Sup">b</span>)</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">Placebo</span><br><span class="Bold">n = 5,429</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">CE</span><br><span class="Bold">n = 5,310</span>
</td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="bottom"><span class="Bold">Absolute Risk per 10,000 Women-Years</span></td></tr>
</thead>
<tfoot><tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top">
<p class="First"><span class="Sup">a</span> Adapted from <span class="Italics">JAMA</span>. 2004;291:1701-1712.</p>
<p><span class="Sup">b</span> Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. </p>
<p><span class="Sup">c</span> Results are based on centrally adjudicated data for an average follow-up of 7.1 years. </p>
<p><span class="Sup">d</span> Results are based on an average follow-up of 6.8 years. </p>
<p><span class="Sup">e</span> Not included in Global Index. </p>
<p><span class="Sup">f</span> All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast or colorectal cancer, definite/probable CHD, PE or cerebrovascular disease. </p>
<p><span class="Sup">g</span> A subset of the events was combined in a "global index," defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes. </p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top">CHD events<span class="Sup">c</span>
</td>
<td class="Rrule" align="center" valign="top">0.95 (0.79-1.16)</td>
<td class="Rrule" align="center" valign="top">56</td>
<td class="Rrule" align="center" valign="top">53</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="Italics">Non-fatal MI </span><span class="Sup">c</span>
</td>
<td class="Rrule" align="center" valign="top"><span class="Italics">0.91 (0.73-1.14)</span></td>
<td class="Rrule" align="center" valign="top"><span class="Italics">43</span></td>
<td class="Rrule" align="center" valign="top"><span class="Italics">40</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">  <span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </span><span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">1.01 (0.71-1.43)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">16</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">16</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Invasive breast cancer<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.80 (0.62-1.04)</td>
<td class="Botrule Rrule" align="center" valign="top">34</td>
<td class="Botrule Rrule" align="center" valign="top">28</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span><span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.39 (1.10-1.77)</td>
<td class="Botrule Rrule" align="center" valign="top">32</td>
<td class="Botrule Rrule" align="center" valign="top">44</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><span class="Sup">c,e</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.47 (1.06-2.06)</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule Rrule" align="center" valign="top">23</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span><span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.37 (0.90-2.07)</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Colorectal cancer<span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.08 (0.75-1.55)</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.61 (0.41-0.91)</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><span class="Sup">d,e</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.62 (0.42-0.93)</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">d,e</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.70 (0.63-0.79)</td>
<td class="Botrule Rrule" align="center" valign="top">195</td>
<td class="Botrule Rrule" align="center" valign="top">139</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to other causes<span class="Sup">d,f</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.08 (0.88-1.32)</td>
<td class="Botrule Rrule" align="center" valign="top">50</td>
<td class="Botrule Rrule" align="center" valign="top">53</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Overall mortality<span class="Sup">d,e</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.04 (0.88-1.22)</td>
<td class="Botrule Rrule" align="center" valign="top">78</td>
<td class="Botrule Rrule" align="center" valign="top">81</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Global index<span class="Sup">d,g</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.01 (0.91-1.12)</td>
<td class="Botrule Rrule" align="center" valign="top">190</td>
<td class="Botrule Rrule" align="center" valign="top">192</td>
</tr>
</tbody>
</table>
<p>For those outcomes included in the WHI "global index," that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE 0.625 mg alone were 12 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while the absolute risk reduction per 10,000 women-years was 6 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. The absolute excess risk of events included in the "global index" was a nonsignificant 2 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. (See <span class="Bold"><a href="#id_6d88b72a-e877-4ec9-9205-6280d6b79429">BOXED WARNINGS</a>, <a href="#i4i_warnings_id_4c11546d-d1d7-49f4-a3ea-0ea5104e6ae1">WARNINGS</a>,</span> and <span class="Bold"><a href="#i4i_precautions_id_becdba40-f5f7-44eb-8c1f-0536423fa603">PRECAUTIONS</a></span>.)</p>
<p>The CE/MPA substudy was also stopped early because, according to predefined stopping rule, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the "global index." Results of the CE/MPA substudy, which included 16,608 women (average age of 63 years, range 50 to 79; 83.9% White, 6.8% Black, 5.4% Hispanic, 3.9% Other) after an average follow-up of 5.6 years, are presented in <span class="Bold"><a href="#id_9359a0ad-442c-4e38-8a3a-a86710b6cee3">Table 4</a></span>:</p>
<a name="id_9359a0ad-442c-4e38-8a3a-a86710b6cee3"></a><table border="1">
<caption><span>TABLE 4 - Relative and Absolute Risk Seen in the CE/MPA Substudy of WHI at an Average of 5.6 Years<span class="Sup">a</span></span></caption>
<col width="192px">
<col width="168px">
<col width="168px">
<col width="168px">
<tfoot><tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top">
<p class="First"><span class="Sup">a</span>   Results are based on centrally adjudicated data. Mortality data was not part of the adjudicated data; however, data at 5.2 years of follow-up showed no difference between the groups in terms of all-cause mortality (RR 0.98, 95% nCI 0.82-1.18). </p>
<p><span class="Sup">b</span>   Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</p>
<p><span class="Sup">c</span>   Includes metastatic and non-metastatic breast cancer with the exception of <span class="Italics">in situ</span> breast cancer. </p>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Event<span class="Sup">c</span></span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">
<span class="Bold">Relative Risk</span><br><span class="Bold">CE/MPA vs. Placebo</span><br><span class="Bold">(95% nCI<span class="Sup">b</span></span><span class="Bold">)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">n = 8,102</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">CE/MPA</span><br><span class="Bold">n = 8,506</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Absolute Risk per 10,000 Women-Years</span></td></tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">CHD events</td>
<td class="Rrule" align="center" valign="top">1.24 (1.00-1.54)</td>
<td class="Rrule" align="center" valign="top">33</td>
<td class="Rrule" align="center" valign="top">39</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="Italics">Non-fatal MI</span>
</td>
<td class="Rrule" align="center" valign="top"><span class="Italics">1.28 (1.00-1.63)</span></td>
<td class="Rrule" align="center" valign="top"><span class="Italics">25</span></td>
<td class="Rrule" align="center" valign="top"><span class="Italics">31</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">  <span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>
</td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">1.10 (0.70-1.75)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">8</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">8</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Invasive breast cancer<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.24 (1.01-1.54)</td>
<td class="Botrule Rrule" align="center" valign="top">33</td>
<td class="Botrule Rrule" align="center" valign="top">41</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td class="Botrule Rrule" align="center" valign="top">1.31 (1.02-1.68)</td>
<td class="Botrule Rrule" align="center" valign="top">24</td>
<td class="Botrule Rrule" align="center" valign="top">31</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1.44 (1.09-1.90)</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span></td>
<td class="Botrule Rrule" align="center" valign="top">1.95 (1.43-2.67)</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></td>
<td class="Botrule Rrule" align="center" valign="top">2.13 (1.45-3.11)</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Invasive Colorectal cancer</td>
<td class="Botrule Rrule" align="center" valign="top">0.56 (0.38-0.81)</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Endometrial cancer</td>
<td class="Botrule Rrule" align="center" valign="top">0.81 (0.48-1.36)</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Cervical cancer</td>
<td class="Botrule Rrule" align="center" valign="top">1.44 (0.47-4.42)</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span></td>
<td class="Botrule Rrule" align="center" valign="top">0.67 (0.47-0.96)</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span></td>
<td class="Botrule Rrule" align="center" valign="top">0.65 (0.46-0.92)</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span></td>
<td class="Botrule Rrule" align="center" valign="top">0.71 (0.59-0.85)</td>
<td class="Botrule Rrule" align="center" valign="top">62</td>
<td class="Botrule Rrule" align="center" valign="top">44</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span></td>
<td class="Botrule Rrule" align="center" valign="top">0.76 (0.69-0.83)</td>
<td class="Botrule Rrule" align="center" valign="top">199</td>
<td class="Botrule Rrule" align="center" valign="top">152</td>
</tr>
</tbody>
</table>
<p>For those outcomes included in the WHI "global index" that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE/MPA were 6 more CHD events, 7 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 7 fewer colorectal cancers and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. The absolute excess risk of events included in the "global index" was 19 per 10,000 women-years (RR 1.15, 95% nCI 1.03-1.28). (See <span class="Bold"><a href="#id_6d88b72a-e877-4ec9-9205-6280d6b79429">BOXED WARNINGS</a>, <a href="#i4i_warnings_id_4c11546d-d1d7-49f4-a3ea-0ea5104e6ae1">WARNINGS</a>,</span> and <span class="Bold"><a href="#i4i_precautions_id_becdba40-f5f7-44eb-8c1f-0536423fa603">PRECAUTIONS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_507d2ddb-e760-49e9-b7e6-c1f7127e6ec2"></a><a name="section-4.3"></a><p></p>
<h2>Women's Health Initiative Memory Study</h2>
<p class="First">The estrogen-alone Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI, enrolled 2,947 predominantly healthy postmenopausal women 65 years of age and older (45% were aged 65 to 69 years, 36% were 70 to 74 years, and 19% were 75 years of age and older) to evaluate the effects of conjugated estrogens (CE 0.625 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo.</p>
<p>After an average follow-up of 5.2 years, 28 women in the CE-alone group (37 per 10,000 women-years) and 19 in the placebo group (25 per 10,000 women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the CE-alone group was 1.49 (95% confidence interval [CI], 0.83-2.66) compared to placebo. It is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#id_6d88b72a-e877-4ec9-9205-6280d6b79429">BOXED WARNINGS</a>, <a href="#i4i_section_id_f5986d17-0edb-474d-b355-62581873c0ff">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a>,</span> and <span class="Bold"><a href="#i4i_geriatric_use_id_ec4c1dd0-e133-40dd-a6b9-2e707fb97c6a">PRECAUTIONS, Geriatric Use</a></span>.)</p>
<p>The CE/MPA WHIMS substudy enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47% were age 65 to 69 years, 35% were 70 to 74 years, and 18% were 75 years of age and older) to evaluate the effects of conjugated estrogens (CE 0.625 mg) plus medroxyprogesterone acetate (MPA 2.5 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo.</p>
<p>After an average follow-up of 4 years, 40 women in the CE/MPA group (45 per 10,000 women-years) and 21 in the placebo group (22 per 10,000 women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the hormone therapy group was 2.05 (95% CI, 1.21-3.48) compared to placebo.</p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95% CI, 1.19-2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#id_6d88b72a-e877-4ec9-9205-6280d6b79429">BOXED WARNING</a></span> and <span class="Bold"><a href="#i4i_section_id_f5986d17-0edb-474d-b355-62581873c0ff">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span><span class="Bold">,</span> and <span class="Bold"><a href="#i4i_geriatric_use_id_ec4c1dd0-e133-40dd-a6b9-2e707fb97c6a">PRECAUTIONS, Geriatric Use</a></span><span class="Bold">.</span>)</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_2c3f00d3-5e35-45a5-9cbe-b51fa0a6bedb"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Elestrin<span class="Sup">®</span> 0.87 g/day and 1.7 g/day are indicated in the:</p>
<p>Treatment of moderate-to-severe vasomotor symptoms associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_767f76ab-21e8-42b4-9b29-e4fd0e5e386f"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Estrogen products, including Elestrin<span class="Sup">®</span>, should not be used in women with any of the following conditions:</p>
<ol>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>Known, suspected, or history of cancer of the breast.</li>
<li>Known or suspected estrogen-dependent neoplasia.</li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, or history of these conditions.</li>
<li>Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>).</li>
<li>Liver dysfunction or disease.</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the ingredients of Elestrin<span class="Sup">®</span>.</li>
<li>Known or suspected pregnancy. There is no indication for Elestrin<span class="Sup">®</span> in pregnancy. There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (See <span class="Bold"><a href="#i4i_precautions_id_becdba40-f5f7-44eb-8c1f-0536423fa603">PRECAUTIONS</a></span>.)</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_4c11546d-d1d7-49f4-a3ea-0ea5104e6ae1"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <span class="Bold"><a href="#id_6d88b72a-e877-4ec9-9205-6280d6b79429">BOXED WARNINGS</a></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1a486a0f-5c4b-4ac3-aa40-512c2cc1d0d0"></a><a name="section-7.1"></a><p></p>
<h2>1. <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></h2>
<p class="First">Estrogen-alone therapy has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT).</p>
<p>Estrogen plus progestin therapy has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> as well as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>. Should any of these events occur or be suspected, estrogens should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or VTE (e.g., personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ebf328eb-1f39-41a8-95da-7c3418b9d221"></a><a name="section-7.1.1"></a><p></p>
<h3>a. <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></h3>
<p class="First">In the WHI estrogen-alone substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women receiving CE 0.625 mg daily compared to placebo (44 versus 32 per 10,000 women-years). The increase in risk was observed in year 1 and persisted. (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a>.</span>)</p>
<p>In the CE/MPA substudy of WHI, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women receiving CE/MPA daily compared to women receiving placebo (31 versus 24 per 10,000 women-years). The increase in risk was demonstrated after the first year and persisted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2fae831c-9404-4eb2-9835-a296df68c038"></a><a name="section-7.1.2"></a><p></p>
<h3>b. Coronary heart disease</h3>
<p class="First">In the estrogen-alone substudy of WHI, no overall effect on coronary heart disease (CHD) events (defined as nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was reported in women receiving estrogen alone compared to placebo. (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a>.</span>)</p>
<p>In the estrogen plus progestin substudy of WHI, no statistically significant increase of CHD events was reported in women receiving CE/MPA compared to women receiving placebo (39 versus 33 per 10,000 women-years). An increase in relative risk was demonstrated in year one, and a trend toward decreasing relative risk was reported in years 2 through 5.</p>
<p>In postmenopausal women with documented heart disease (n = 2,763, average age 66.7 years), a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study (HERS) treatment with CE/MPA (0.625 mg/2.5 mg per day) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE/MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE/MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Participation in an open label extension of the original HERS trial (HERS II) was agreed to by 2,321 women. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE/MPA group and the placebo group in HERS, HERS II, and overall.</p>
<p>Large doses of estrogen (5 mg conjugated equine estrogens per day), comparable to those used to treat cancer of the prostate and breast, have been shown in a large prospective clinical trial in men to increase the risk of nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a997840-fda4-4125-8953-ab13278eeaad"></a><a name="section-7.1.3"></a><p></p>
<h3>c. <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span> (VTE)</h3>
<p class="First">In the estrogen-alone substudy of WHI, the risk of VTE (DVT and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> [PE]) was reported to be increased for women receiving CE compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first two years. (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a>.</span>)</p>
<p>In the CE/MPA substudy of WHI, a statistically significant two-fold greater rate of VTE was reported in women receiving CE/MPA compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was observed during the first year and persisted. (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a>.</span>)</p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cf34fe55-9074-4f3c-8a35-6f88c58eedf4"></a><a name="section-7.2"></a><p></p>
<h2>2. Malignant neoplasms</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fd9f3d65-ad23-4e0e-b9f9-d84e3761df76"></a><a name="section-7.2.1"></a><p></p>
<h3><span class="Bold">a. Endometrial cancer</span></h3>
<p class="First">The use of unopposed estrogens by women with intact uteri has been associated with an increased risk of endometrial cancer. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with an increased risk of 15- to 24-fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</p>
<p>Clinical surveillance of all women taking estrogen/progestin combinations is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer.</p>
<p>In a 12-week clinical trial, one case of complex <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> with atypia was reported in the Elestrin<span class="Sup">®</span> 1.7 g/day dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_965bfadd-dafd-4313-a958-a3a0d2f4b24f"></a><a name="section-7.2.2"></a><p></p>
<h3><span class="Bold">b. Breast Cancer</span></h3>
<p class="First">The use of estrogens and progestins by postmenopausal women has been reported to increase the risk of breast cancer. The most important randomized clinical trial providing information about this issue is the Women's Health Initiative (WHI) (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a></span>). The results from observational studies are generally consistent with those of the WHI clinical trial and report no significant variation in the risk of breast cancer among different estrogens or progestins, doses, or routes of administration.</p>
<p>In the estrogen-alone substudy of WHI, after an average of 7.1 years of follow-up, CE (0.625 mg daily) was not associated with an increased risk of invasive breast cancer (RR 0.80, 95% nCI 0.62-1.04).</p>
<p>The CE/MPA substudy of WHI study reported an increased risk of breast cancer in women who took CE/MPA for a mean follow-up of 5.6 years. Observational studies have also reported an increased risk for estrogen/progestin combination therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. In the WHI trial and from observational studies, the excess risk increased with duration of use. From observational studies, the risk appeared to return to baseline in about 5 years after stopping treatment. In addition, observational studies suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen/progestin combination therapy as compared to estrogen-alone therapy.</p>
<p>In the CE/MPA substudy, 26% of the women reported prior use of estrogen-alone and/or estrogen/progestin combination hormone therapy. After a mean follow-up of 5.6 years during the clinical trial, the relative risk of invasive breast cancer was 1.24 (95% nCI, 1.01-1.54), and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE/MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for CE/MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years, for CE/MPA compared with placebo. In the same substudy, invasive breast cancers were larger and diagnosed at a more advanced stage in the CE/MPA group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare with no apparent difference between the two groups. Other prognostic factors such as histologic subtype, grade and hormone receptor status did not differ between the groups.</p>
<p>The use of estrogen alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5986d17-0edb-474d-b355-62581873c0ff"></a><a name="section-7.3"></a><p></p>
<h2>3. <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></h2>
<p class="First">In the estrogen-alone WHIMS, a substudy of WHI, a population of 2,947 hysterectomized women aged 65 to 79 years was randomized to CE (0.625 mg daily) or placebo. In the estrogen plus progestin WHIMS, a population of 4,532 postmenopausal women aged 65 to 79 years was randomized to CE/MPA (0.625 mg/2.5 mg daily) or placebo.</p>
<p>In the estrogen-alone substudy, after an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for estrogen alone versus placebo was 1.49 (95% CI, 0.83-2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for estrogen-alone versus placebo was 37 versus 25 cases per 10,000 women-years. It is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a></span> and <span class="Bold"><a href="#i4i_geriatric_use_id_ec4c1dd0-e133-40dd-a6b9-2e707fb97c6a">PRECAUTIONS, Geriatric Use</a></span><span class="Bold">.</span>)</p>
<p>In the estrogen plus progestin substudy, after an average follow-up of 4 years, 40 women in the estrogen plus progestin group and 21 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for estrogen plus progestin versus placebo was 2.05 (95% CI, 1.21-3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE/MPA versus placebo was 45 versus 22 cases per 10,000 women-years. (See <span class="Bold"><a href="#i4i_clinical_studies_id_eb3a8acd-9d39-4a3c-a96c-becdddf0ed5c">CLINICAL STUDIES</a></span> and <span class="Bold"><a href="#i4i_geriatric_use_id_ec4c1dd0-e133-40dd-a6b9-2e707fb97c6a">PRECAUTIONS, Geriatric Use</a></span><span class="Bold">.</span>)</p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95% CI, 1.19-2.60). Since both substudies were conducted in women 65 to 79 years, it is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#id_6d88b72a-e877-4ec9-9205-6280d6b79429">BOXED WARNINGS</a></span> and <span class="Bold"><a href="#i4i_geriatric_use_id_ec4c1dd0-e133-40dd-a6b9-2e707fb97c6a">PRECAUTIONS, Geriatric Use</a></span><span class="Bold">.</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8a637d75-65fc-427e-9ba5-aa7ebae1ea44"></a><a name="section-7.4"></a><p></p>
<h2>4. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></h2>
<p class="First">A 2- to 4-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3ed7362-97f0-4fc1-9c11-007f7a857628"></a><a name="section-7.5"></a><p></p>
<h2>5. <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in patients with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fbcd25a5-5cca-4b4f-ac2b-5d2481d80119"></a><a name="section-7.6"></a><p></p>
<h2>6. Visual abnormalities</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in patients receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_becdba40-f5f7-44eb-8c1f-0536423fa603"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_a2e24edb-7e8c-4814-8d37-1b17f933c4a8"></a><a name="section-8.1"></a><p></p>
<h2>A. General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e16dbc6-ed9d-4a9c-bb0f-f235c73b27ea"></a><a name="section-8.1.1"></a><p></p>
<h3>1. Addition of a progestin when a woman has not had a hysterectomy</h3>
<p class="First">Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would be induced by estrogen treatment alone. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer.</p>
<p>There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include a possible increased risk of breast cancer, adverse effects on lipoprotein metabolism (e.g., lowering HDL, raising LDL), and impairment of glucose tolerance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67b39380-7aa0-483e-afb3-c2a4f05e7005"></a><a name="section-8.1.2"></a><p></p>
<h3>2. Elevated blood pressure</h3>
<p class="First">In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen. Blood pressure should be monitored at regular intervals with estrogen use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0d579edd-fdbb-4400-bfbc-3eda118fd265"></a><a name="section-8.1.3"></a><p></p>
<h3>3. <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h3>
<p class="First">In patients with preexisting <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and other complications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79aee6a6-cf83-4c72-9af5-7eb0390b46a6"></a><a name="section-8.1.4"></a><p></p>
<h3>4. <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired liver function</span> and past history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span></h3>
<p class="First">Estrogens may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For patients with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9593a73-53a3-469d-b02f-e830174cddd5"></a><a name="section-8.1.5"></a><p></p>
<h3>5. <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h3>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Patients with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the normal range. Patients dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These patients should have their thyroid function monitored to maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b57fa91a-f952-4e4a-8368-687462b90fee"></a><a name="section-8.1.6"></a><p></p>
<h3>6. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></h3>
<p class="First">Estrogens may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Because of this, patients who have conditions that might be influenced by this factor, such as a cardiac or renal dysfunction, warrant careful observation when estrogens are prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fc85a1d9-5751-47b3-ac5f-ac4bd16031c5"></a><a name="section-8.1.7"></a><p></p>
<h3>7. <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h3>
<p class="First">Estrogens should be used with caution in individuals with severe <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4cb43b6a-4aa2-4eef-88aa-91d5d9b5d409"></a><a name="section-8.1.8"></a><p></p>
<h3>8. Ovarian cancer</h3>
<p class="First">The CE/MPA substudy of WHI study reported that after an average follow-up of 5.6 years, the relative risk for ovarian cancer for estrogen plus progestin versus placebo was 1.58 (95% nCI, 0.77 – 3.24) but was not statistically significant. The absolute risk for estrogen plus progestin versus placebo was 4.2 versus 2.7 cases per 10,000 women-years. In some epidemiologic studies, the use of estrogen alone, in particular for 10 or more years, has been associated with an increased risk of ovarian cancer. Other epidemiologic studies have not found these associations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_573b3a51-3010-45a6-b8b8-fdf74c93dbbc"></a><a name="section-8.1.9"></a><p></p>
<h3>9. Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> may be exacerbated with administration of estrogens. A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For patients known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5217bdf6-ae72-4d2f-9e0e-77ef10f4ef3e"></a><a name="section-8.1.10"></a><p></p>
<h3>10. Exacerbation of other conditions</h3>
<p class="First">Estrogen therapy may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e8098055-da40-4ff2-ba69-605944168d50"></a><a name="section-8.1.11"></a><p></p>
<h3>11. <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/Photoallergy</h3>
<p class="First">Increased sensitivity to direct exposure to the sun on areas of Elestrin<span class="Sup">®</span> application has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7eefaee-aeb3-419b-95bd-74eacf38b40c"></a><a name="section-8.1.12"></a><p></p>
<h3>12. Sunscreen application</h3>
<p class="First">Estradiol absorption was increased when sunscreen was applied 10 minutes before Elestrin<span class="Sup">®</span>application. Sunscreen should not be applied to the same site until at least 25 minutes after the application of Elestrin.</p>
<p>Concomitant application of sunscreen and Elestrin® to the same application site for 7 or more days may increase estradiol absorption. Avoid applying sunscreen to the area of Elestrin<span class="Sup">®</span> application for an extended period of 7 or more days. (See <span class="Bold"><a href="#i4i_section_id_873f3997-0878-48a7-8d9f-f680687c8ba3">CLINICAL PHARMACOLOGY, Absorption</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5280d25-1718-4afa-a83b-cc0f7a7468d8"></a><a name="section-8.1.13"></a><p></p>
<h3>13. Miscellaneous</h3>
<p class="First">Alcohol based gels potentially are flammable. Avoid fire, flame, or smoking until the gel has dried.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_d62f4024-6e89-4d9a-8e8c-3c12004760a6"></a><a name="section-8.2"></a><p></p>
<h2>B. Information for Patients</h2>
<p class="First">Physicians are advised to discuss the Patient Information leaflet with patients for whom they prescribe Elestrin<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_54d38b53-65fa-4a4e-bd32-9a9806491ab6"></a><a name="section-8.3"></a><p></p>
<h2>C. Laboratory Tests</h2>
<p class="First">Estrogen administration should be initiated at the lowest dose approved for the treatment of postmenopausal moderate to severe vasomotor symptoms and then guided by clinical response rather than by serum hormone levels (e.g., estradiol, FSH).</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_3793faeb-50f0-4246-a8c4-b3ecefdc18d0"></a><a name="section-8.4"></a><p></p>
<h2>D. Drug/Laboratory Test Interactions</h2>
<ol>
<li>Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity.</li>
<li>Increased <span class="product-label-link" type="condition" conceptid="4188578" conceptname="Thyroxine binding globulin">thyroid binding globulin</span> (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T<span class="Sub">4</span> levels (by column or by radioimmunoassay) or T<span class="Sub">3</span> levels by radioimmunoassay. T<span class="Sub">3</span> resin uptake is decreased, reflecting the elevated TBG. Free T<span class="Sub">4</span> and free T<span class="Sub">3</span> concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.</li>
<li>Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin [CBG], SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>).</li>
<li>Increased plasma HDL and HDL<span class="Sub">2</span> <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> subfraction concentrations, reduced LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased triglycerides levels.</li>
<li>Impaired glucose tolerance.</li>
<li>Reduced response to metyrapone test.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_87fd403c-edf1-4640-8519-218c0cf1a15f"></a><a name="section-8.5"></a><p></p>
<h2>E. Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term continuous administration of estrogen, with or without progestin, in women with or without a uterus, has shown an increased risk of endometrial cancer, breast cancer, and ovarian cancer. (See <span class="Bold"><a href="#id_6d88b72a-e877-4ec9-9205-6280d6b79429">BOXED WARNINGS</a></span>, <span class="Bold"><a href="#i4i_warnings_id_4c11546d-d1d7-49f4-a3ea-0ea5104e6ae1">WARNINGS</a></span> and <span class="Bold"><a href="#i4i_precautions_id_becdba40-f5f7-44eb-8c1f-0536423fa603">PRECAUTIONS</a></span>.)</p>
<p>Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_d144ed36-651f-469b-94be-027813013c65"></a><a name="section-8.6"></a><p></p>
<h2>F. Pregnancy</h2>
<p class="First">Estrogen products, including Elestrin, should not be used during pregnancy. (See <span class="Bold"><a href="#i4i_contraindications_id_767f76ab-21e8-42b4-9b29-e4fd0e5e386f">CONTRAINDICATIONS</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_3927547d-d40a-48fa-9fd4-8f6a44ada06c"></a><a name="section-8.7"></a><p></p>
<h2>G. Nursing Mothers</h2>
<p class="First">Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of the milk. Detectable amounts of estrogens have been identified in the milk of mothers receiving this drug. Caution should be exercised when estrogen products, including Elestrin, are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_5760ea07-c944-488a-a32f-b808eda9e19c"></a><a name="section-8.8"></a><p></p>
<h2>H. Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_ec4c1dd0-e133-40dd-a6b9-2e707fb97c6a"></a><a name="section-8.9"></a><p></p>
<h2>I. Geriatric Use</h2>
<p class="First">Clinical studies of Elestrin<span class="Sup">®</span> did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
<p>Of the total number of subjects in the estrogen-alone substudy of the WHI study, 46% (n = 4,943) were 65 years and older, while 7.1% (n = 767) were 75 years and older. There was a higher relative risk (CE versus placebo) of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women less than 75 years of age compared to women 75 years and older.</p>
<p>In the estrogen-alone substudy of the WHIMS, a population of 2,947 hysterectomized women, aged 65 to 79 years, was randomized to estrogen alone (CE 0.625 mg) or placebo. After an average follow-up of 5.2 years, the relative risk (CE versus placebo) of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.49 (95% CI, 0.83-2.66). The absolute risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> with estrogen alone was 37 versus 25 cases per 10,000 women-years.</p>
<p>Of the total number of subjects in the CE/MPA substudy of the WHI, 44% (n = 7,320) were 65 years and older, while 6.6% (n = 1,095) were 75 years and older. There was a higher relative risk (CE/MPA versus placebo) of non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer in women 75 and older compared to women less than 75 years of age. In women greater than 75, the increased risk of non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer observed in the estrogen plus progestin combination group compared to the placebo group was 75 versus 24 per 10,000 women-years and 52 versus 12 per 10,000 women years, respectively.</p>
<p>In the estrogen plus progestin substudy of WHIMS, a population of 4,532 postmenopausal women, aged 65 to 70 years, was randomized to conjugated estrogens (CE 0.625 mg) plus medroxyprogesterone acetate (MPA 2.5 mg) or placebo. In the estrogen plus progestin group, after an average follow-up of 4 years, the relative risk (CE/MPA versus placebo) of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 2.05 (95% CI, 1.21-3.48). The absolute risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> with CE/MPA was 45 versus 22 per 10,000 women-years.</p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95% CI, 1.19-2.60). Since both substudies were conducted in women aged 65 to 79 years, it is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#id_6d88b72a-e877-4ec9-9205-6280d6b79429">BOXED WARNINGS</a></span> and <span class="Bold"><a href="#i4i_section_id_f5986d17-0edb-474d-b355-62581873c0ff">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_20f6e94f-3dd9-41cd-8e97-3f75dce2f4c1"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">See <span class="Bold"><a href="#id_6d88b72a-e877-4ec9-9205-6280d6b79429">BOXED WARNINGS</a></span>, <span class="Bold"><a href="#i4i_warnings_id_4c11546d-d1d7-49f4-a3ea-0ea5104e6ae1">WARNINGS</a></span> and <span class="Bold"><a href="#i4i_precautions_id_becdba40-f5f7-44eb-8c1f-0536423fa603">PRECAUTIONS</a></span>. </p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.</p>
<p>Elestrin<span class="Sup">®</span> was studied in a placebo-controlled trial that included a total of 484 postmenopausal women. The adverse events that occurred at a rate greater than 5% in any of the treatment groups are summarized in <span class="Bold"><a href="#id_55783707-2bf3-4061-8210-5c85ba649067">Table 5</a></span>.</p>
<a name="id_55783707-2bf3-4061-8210-5c85ba649067"></a><table border="1">
<caption><span>TABLE 5 - Incidence of Treatment-Emergent Adverse Events Occurring in ≥ 5% of Subjects</span></caption>
<col width="228px">
<col width="148px">
<col width="148px">
<col width="148px">
<thead>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><span class="Bold">Body System / Signs and Symptoms</span></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="bottom"><span class="Bold">Number (%) of Subjects</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><span class="Bold">Placebo<br>(n = 137)</span></td>
<td class="Rrule" align="center" valign="bottom"><span class="Bold">Elestrin<span class="Sup">®</span> 0.87 g/day<br>(n = 136)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Elestrin<span class="Sup">®</span> 1.7 g/day<br>(n = 142)</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Reproductive system &amp; <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">Breast tenderness</span></td>
<td class="Botrule Rrule" align="center" valign="top">5 (3.6)</td>
<td class="Botrule Rrule" align="center" valign="top">9 (6.6)</td>
<td class="Botrule Rrule" align="center" valign="top">11 (7.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">Metrorrhagia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3 (2.2)</td>
<td class="Botrule Rrule" align="center" valign="top">6 (4.4)</td>
<td class="Botrule Rrule" align="center" valign="top">13 (9.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Respiratory, thoracic &amp; <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Botrule Rrule" align="center" valign="top">10 (7.3)</td>
<td class="Botrule Rrule" align="center" valign="top">14 (10.3)</td>
<td class="Botrule Rrule" align="center" valign="top">12 (8.5)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center" valign="top">5 (3.6)</td>
<td class="Rrule" align="center" valign="top">8 (5.9)</td>
<td class="Botrule Rrule" align="center" valign="top">5 (3.5)</td>
</tr>
</tbody>
</table>
<p>The following additional adverse reactions have been reported with estrogen and/or progestin therapy.</p>
<ol>
<li>
<span class="Bold">Genitourinary system</span><br>Changes in <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> pattern and abnormal <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> or flow; breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; spotting; <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>; increase in size of uterine leiomyomata; <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>; change in amount of cervical secretion; changes in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span>; ovarian cancer; <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>; endometrial cancer.</li>
<li>
<span class="Bold">Breasts</span><br><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span>; enlargement, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>; <span class="product-label-link" type="condition" conceptid="78804" conceptname="Fibrocystic disease of breast">fibrocystic breast</span> changes; breast cancer.</li>
<li>
<span class="Bold">Cardiovascular</span><br>Deep and superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>; <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>; <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; increase in blood pressure.</li>
<li>
<span class="Bold">Gastrointestinal</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>; <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>; increased incidence of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, enlargement of hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>.</li>
<li>
<span class="Bold">Skin</span><br><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span> that may persist when drug is discontinued; <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>; hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>; loss of scalp hair; <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</li>
<li>
<span class="Bold">Eyes</span><br>Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, intolerance to contact lenses.</li>
<li>
<span class="Bold">Central nervous system</span><br><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>; <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; mood disturbances; <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>; exacerbation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</li>
<li>
<span class="Bold">Miscellaneous</span><br>Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>; <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; changes in libido; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, anaphylactoid/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>; <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>; <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>; increased triglycerides.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a53628b2-77e5-4ba2-b922-cba6227ff288"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious ill effects have not been reported following acute ingestion of large doses of estrogen-containing products by young children. Overdosage of estrogen may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in females.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b06a23e9-f815-4f0f-8173-92c185ccda3c"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">When estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be re-evaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary (see <span class="Bold"><a href="#id_6d88b72a-e877-4ec9-9205-6280d6b79429">BOXED WARNINGS</a></span> and <span class="Bold"><a href="#i4i_warnings_id_4c11546d-d1d7-49f4-a3ea-0ea5104e6ae1">WARNINGS</a></span>). For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<p>Elestrin<span class="Sup">®</span> is applied once daily to the upper arm for the treatment of moderate to severe vasomotor symptoms associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> using a metered-dose pump which delivers 0.87 gram of estradiol gel per actuation.</p>
<p>Patients should be started with the lowest effective dose of Elestrin<span class="Sup">®</span>, which is one pump actuation per day (0.87 g/day, which contains 0.52 mg of estradiol).</p>
<p>Subsequent dosage adjustment may be made based upon the individual patient response. This dose should be periodically reassessed by the healthcare provider.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_bfff6e19-7308-4b2d-b6af-986efc7676f3"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Elestrin<span class="Sup">®</span> is estradiol 0.06% in a colorless, non-staining hydroalcoholic gel supplied in a non-aerosol, metered-dose pump container constructed of polypropylene. The drug product is contained within a collapsible inner liner/bag consisting of an inner and outer layer of low density polyethylene with a resealable polypropylene cap. Each pump container holds 35 g of gel and is capable of delivering 26 g of gel as 30 metered actuations. Each actuation delivers 0.87 g of gel which contains 0.52 mg of estradiol. Pump containers are packaged individually or as two pump containers together.</p>
<p>NDC 18860-480-30.....Package containing one Elestrin<span class="Sup">® </span>35 g pump container.</p>
<p>NDC 18860-480-60.....Package containing two Elestrin<span class="Sup">® </span>35 g pump containers.</p>
<p>NDC 18860-480-01.....Elestrin<span class="Sup">® </span>35 g pump container. This package is contained within the Carton (18860-480-60).</p>
<p><span class="Bold">KEEP OUT OF THE REACH OF CHILDREN; THE PUMP CONTAINER IS NOT CHILD-RESISTANT.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cf387782-5e29-40a9-80e1-f9358f2b35d5"></a><a name="section-12.1"></a><p></p>
<p class="First">Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c1abd113-fc16-4981-8994-6b5e6dc064b7"></a><a name="section-13"></a><p></p>
<p class="First">Elestrin<span class="Sup">®</span> is a trademark of Azur Pharma International II Limited</p>
<p>Distributed by:</p>
<div class="Figure"><img alt="Azur Pharma Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e1a3641-25ca-41bd-a940-51ae0ec64ed9&amp;name=f3f8fca9-1981-471d-89f5-6b7fbb8f49d6-03.jpg"></div>
<p>1818 Market Street, Suite 2350, Philadelphia, PA 19103 • www.azurpharma.com</p>
<p>Manufactured by: <br><span class="Bold">DPT Laboratories, Ltd</span><br>San Antonio, TX 78215</p>
<p>U.S. Pat. No. 7,198,801 and U.S. Pat. No. 7,470,433</p>
<p>©2010 Azur Pharma International II LImited</p>
<p>129450-6010</p>
<p>Rev. 01/2011</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_7c1fb975-8e72-481d-a5c6-2d45b8454573"></a><a name="section-14"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">Elestrin<span class="Sup">®</span></span><br><span class="Bold">(estradiol gel)</span></p>
<p>By prescription only</p>
<p>Read this Patient Information leaflet before you start using Elestrin<span class="Sup">®</span> and read what you get each time you refill your Elestrin<span class="Sup">®</span> prescription. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition and your treatment.</p>
<div class="Warning">
<a name="id_796041c0-aaf7-4fe6-86ef-7f6521ea7858"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT Elestrin<span class="Sup">®</span> (AN ESTROGEN HORMONE)?</span></p>
<ul><li>Estrogens increase the chances of getting cancer of the uterus.</li></ul>
<p>Report any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> right away while you are using Elestrin<span class="Sup">®</span>. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</p>
<ul><li>Do not use estrogens with or without progestins to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>.</li></ul>
<p>Using estrogens with or without progestins may increase your chances of getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, and blood clots.</p>
<ul>
<li>Do not use estrogens with or without progestins to prevent <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</li>
<li>Using estrogens with or without progestins may increase your risk of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women age 65 years or older.</li>
</ul>
<p>You and your healthcare provider should talk regularly about whether you still need treatment with Elestrin<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d8ad92ba-418e-4fc7-b0ee-5ee540038a9e"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">What is Elestrin?</span></p>
<p>Elestrin<span class="Sup">®</span> is a medicine in a colorless gel that contains an estrogen hormone (estradiol) which is absorbed through the skin into the bloodstream.</p>
<p><span class="Bold">What is Elestrin<span class="Sup">®</span> used for?</span></p>
<p>Elestrin<span class="Sup">®</span> is used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to:</p>
<ul><li>
<span class="Bold">Reduce moderate-to-severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span></span><br>Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 to 55 years old. This drop in body estrogen levels causes the "change of life" or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (the end of monthly menstrual periods). Sometimes, both ovaries are removed during an operation before natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> takes place. The sudden drop in estrogen levels causes "<span class="product-label-link" type="condition" conceptid="440155" conceptname="Postartificial menopausal syndrome">surgical menopause</span>."<br>When the estrogen levels begin dropping, some women develop very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden strong feelings of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> ("<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>" or "<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>"). In some women, the symptoms are mild, and they will not need estrogens. In other women, symptoms can be more severe. You and your healthcare provider should talk regularly about whether you still need treatment with Elestrin<span class="Sup">®</span>.</li></ul>
<p><span class="Bold">Who should not use Elestrin<span class="Sup">®</span>?</span></p>
<p>Do not start using Elestrin<span class="Sup">®</span> if you:</p>
<ul>
<li><span class="Bold">Have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span></li>
<li>
<span class="Bold">Currently have or have had certain cancers</span><br>Estrogens may increase the chances of getting certain types of cancers, including cancer of the breast or uterus. If you have or had cancer, talk with your healthcare provider about whether you should use Elestrin<span class="Sup">®</span>.</li>
<li><span class="Bold">Had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> in the past year</span></li>
<li><span class="Bold">Currently have or have had blood clots</span></li>
<li><span class="Bold">Currently have or have had liver problems</span></li>
<li>
<span class="Bold">Are allergic to Elestrin<span class="Sup">®</span> or any of its ingredients</span><br>See below for a list of ingredients in Elestrin<span class="Sup">®</span>
</li>
<li><span class="Bold">Think you may be pregnant</span></li>
</ul>
<p>Tell your healthcare provider:</p>
<ul>
<li>
<span class="Bold">If you are breastfeeding</span><br>The hormone in Elestrin<span class="Sup">®</span> can pass into your milk.</li>
<li>
<span class="Bold">About all of your medical problems</span><br>Your healthcare provider may need to check you more carefully if you have certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.</li>
<li>
<span class="Bold">About all the medicines you take</span><br>This includes prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how Elestrin<span class="Sup">®</span> works. Elestrin<span class="Sup">®</span> may also affect how your other medicines work.</li>
<li>
<span class="Bold">If you are going to have surgery or will be on bed rest</span><br>You may need to stop using Elestrin<span class="Sup">®</span>.</li>
</ul>
<p><span class="Bold">What are the ingredients in Elestrin<span class="Sup">®</span>?</span></p>
<p>Active ingredient: estradiol.</p>
<p>Inactive ingredients: purified water, ethanol, propylene glycol, diethylene glycol monoethyl ether, carbomer 940, triethanolamine, and edetate disodium.</p>
<p><span class="Bold">How should I use Elestrin<span class="Sup">®</span>?</span></p>
<ol>
<li>Start at the lowest dose and talk to your healthcare provider about how well that dose is working for you.</li>
<li>Elestrin<span class="Sup">®</span> should be used at the lowest dose possible for your treatment and only as long as needed. You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about the dose you are taking and whether you still need treatment with Elestrin<span class="Sup">®</span>.</li>
</ol>
<p>Elestrin<span class="Sup">®</span> comes in a metered-dose pump container. One actuation of Elestrin<span class="Sup">® </span>is released each time the pump is depressed (pressed down).</p>
<p>Use Elestrin<span class="Sup">®</span> exactly how your healthcare provider tells you.</p>
<p>The Elestrin<span class="Sup">®</span> pump container holds enough of the medicine to let you prime the pump before you use it the first time. To prime, actuate the pump until gel is dispensed. Discard the first actuation that produces gel as this will not contain a full actuation. The pump is now primed and ready to use. Use the pump a total of 30 times (30 actuations) as prescribed by your healthcare provider. After you have initially primed the pump and have used a total of 30 actuations of Elestrin<span class="Sup">®</span>, you will need to throw the pump container away and use a new one. The correct amount of medicine in each actuation cannot be assured after 30 actuations have been used, even though the pump container is not completely empty.</p>
<p><span class="Bold">Important things to remember when using Elestrin</span><span class="Bold"><span class="Sup">®</span></span></p>
<p><span class="Bold">     Wash your hands with soap and water after applying the gel to reduce the chance that the <br>     medicine will be spread from your hands to other people.</span><br><span class="Bold">     </span>Allow the gel to dry for five minutes or more before dressing. Try to keep the area dry for as long as possible.<br><span class="Bold">     </span>Do not allow others to come in contact with the area of skin where you applied the gel for at least two hours after you apply Elestrin<span class="Sup">®</span>.<br><span class="Bold">     Always place the cap over the top of the pump after each use.</span><br><span class="Bold">     Never apply Elestrin<span class="Sup">®</span> to the breast. Never apply Elestrin<span class="Sup">®</span> in or around the vagina.</span><br><span class="Bold">     </span>Do not allow others to apply the gel for you.<br><span class="Bold">     Do not apply sunscreen to the area where the gel was applied for at least 25 minutes.</span><br><span class="Bold">     Do not apply sunscreen to the area where the gel was applied for 7 or more consecutive days.</span><br><span class="Bold">     Avoid fire, flame or smoking until the gel has dried. Elestrin<span class="Sup">®</span> contains alcohol. Alcohol based gels are flammable.</span></p>
<p><span class="Bold">It is important that you read and follow the detailed "Patient Instructions for Use" at the end of this leaflet on how to use the Elestrin<span class="Sup">®</span> pump and apply the dose.</span></p>
<p><span class="Bold">What should I do if someone else is exposed to Elestrin?</span></p>
<p>If someone else is exposed to Elestrin<span class="Sup">®</span> by direct contact with the gel, that person should wash the area of contact with soap and water as soon as possible. The longer the gel is in contact with the skin before washing, the greater is the chance that the other person will absorb some of the estrogen hormone. This is especially important for men and children.</p>
<p><span class="Bold">What should I do if I get Elestrin<span class="Sup">®</span> in my eyes?</span></p>
<p>If you get Elestrin<span class="Sup">®</span> in your eyes, rinse your eyes right away with warm clean water to flush out any Elestrin<span class="Sup">®</span>. Seek medical attention if needed.</p>
<p><span class="Bold">What should I do if I miss a dose?</span></p>
<p>If you miss a dose, do not double the dose on the next day to catch up. If your next dose is less than 12 hours away, it is best just to wait and apply your normal dose the next day. If it is more than 12 hours until the next dose, apply the dose you missed and resume your normal dosing the next day.</p>
<p><span class="Bold">What are the possible side effects of estrogens?</span></p>
<p><span class="Bold">Less common but serious side effects include:</span></p>
<ul>
<li>Breast cancer</li>
<li>Cancer of the uterus</li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span></li>
<li>Blood clots</li>
<li><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></li>
<li>Ovarian cancer</li>
</ul>
<p><span class="Bold">These are some of the warning signs of serious side effects:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span></li>
<li>Unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and faintness</li>
<li>Changes in speech</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in your legs</li>
<li>Changes in vision</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
</ul>
<p>Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you.</p>
<p><span class="Bold">Common side effects include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span></li>
<li>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting</li>
<li>Stomach/<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span></li>
</ul>
<p><span class="Bold">Other side effects include:</span></p>
<ul>
<li>High blood pressure</li>
<li>Liver problems</li>
<li>High blood sugar</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></li>
<li>Enlargement of benign tumors of the uterus ("<span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">fibroids</span>")</li>
<li>Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span></li>
</ul>
<p>These are not all the possible side effects of Elestrin<span class="Sup">®</span>. For more information, ask your healthcare provider or pharmacist.</p>
<p><span class="Bold">What can I do to lower my chances of a serious side effect with Elestrin<span class="Sup">®</span>?</span></p>
<p>Talk with your healthcare provider regularly about whether you should continue using Elestrin<span class="Sup">®</span>. If you have a uterus, talk to your healthcare provider about whether the addition of a progestin is right for you. In general, the addition of a progestin is recommended for women with a uterus to reduce the chance of getting cancer of the uterus. See your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while using Elestrin<span class="Sup">®</span>. Have a breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram, you may need to have breast exams more often. If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have a higher chance for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart disease.</p>
<p><span class="Bold">Have an annual gynecologic exam</span></p>
<p><span class="Bold">General information about safe and effective use of Elestrin<span class="Sup">®</span></span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use Elestrin<span class="Sup">®</span> for conditions for which it was not prescribed. Do not give Elestrin<span class="Sup">®</span> to other people, even if they have the same symptoms you have. It may harm them.</p>
<p><span class="Bold">KEEP OUT OF REACH OF CHILDREN; THE PUMP CONTAINER IS NOT CHILD-RESISTANT</span>.</p>
<p>This leaflet provides a summary of the most important information about Elestrin<span class="Sup">®</span>. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about Elestrin<span class="Sup">®</span> that is written for health professionals. You can get more information by calling <span class="Bold">1-800-890-3098</span> (toll free).</p>
<p>Patient Instructions for Use.</p>
<p><span class="Bold">1. Remove the cap.</span></p>
<p><span class="Bold">2. Prime the pump before using the pump for the first time.</span></p>
<ul>
<li>To prime, actuate the pump until gel is dispensed. Discard the first actuation that produces gel as this will not contain a full actuation. The pump is now primed and ready to use.</li>
<li>Throw away the unused gel by placing it in the trash to avoid another person or pet from accidental contact with the gel, or eating or drinking it.</li>
<li>
<span class="Bold">After priming, the pump is ready to use</span>.<br>One complete actuation will dispense the same amount of Elestrin<span class="Sup">®</span> each time.<br>After each daily dose, <span class="Bold">replace the cap</span> before you put it away.</li>
</ul>
<p><span class="Bold">3. Apply Elestrin<span class="Sup">®</span>.</span></p>
<ul>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span> completely before applying Elestrin<span class="Sup">®</span>.</span><br>You should apply your daily actuation(s) of gel to clean, dry, unbroken skin. If you take a bath or shower or use a sauna, apply Elestrin<span class="Sup">®</span> after your bath, shower, or sauna. If you go swimming, try to leave as much time as possible, at least 2 hours, between applying your Elestrin<span class="Sup">®</span> actuation(s) and going into the water.</li>
<li><span class="Bold">Apply Elestrin<span class="Sup">®</span> at the same time and the same locations each day.</span></li>
</ul>
<p><span class="Bold">Figure 1</span><br>To apply the dose, hold the pump with the tip facing the application area of the arm. For each actuation needed, press the pump firmly and fully with a continuous motion without hesitation.</p>
<div class="Figure"><img alt="Figure 1 -- Image for Applying Elestrin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e1a3641-25ca-41bd-a940-51ae0ec64ed9&amp;name=f3f8fca9-1981-471d-89f5-6b7fbb8f49d6-04.jpg"></div>
<p><span class="Bold">Figure 2</span><br>Gently spread the gel using only 2 fingers. Spread and gently rub in the gel over the entire area of your upper arm and shoulder area, as illustrated.</p>
<div class="Figure"><img alt="Figure 2 -- Image for Spreading Elestrin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e1a3641-25ca-41bd-a940-51ae0ec64ed9&amp;name=f3f8fca9-1981-471d-89f5-6b7fbb8f49d6-05.jpg"></div>
<p><span class="Bold">4. Wash your hands with soap and water.</span></p>
<p>Elestrin<span class="Sup">®</span> should not be used after the date printed on the container (expiration date).</p>
<p>Elestrin<span class="Sup">®</span> is a trademark of Azur Pharma International II Limited</p>
<p>Distributed by:</p>
<div class="Figure"><img alt="Azur Pharma Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e1a3641-25ca-41bd-a940-51ae0ec64ed9&amp;name=f3f8fca9-1981-471d-89f5-6b7fbb8f49d6-06.jpg"></div>
<p>1818 Market Street, Suite 2350, Philadelphia, PA 19103 • www.azurpharma.com • www.elestrin.com</p>
<p>Manufactured by: <br><span class="Bold">DPT Laboratories, Ltd.</span><br>San Antonio, TX 78215</p>
<p>U.S. Pat. No. 7,198,801 and U.S. Pat. No. 7,470,433</p>
<p>©2010 Azur Pharma International II Limited</p>
<p>129450-6010</p>
<p>ELESp-10-01</p>
<p>Rev. 07/10</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_f5e58e5f-2d2f-4f94-a2b6-f947f27f781f"></a><a name="section-15"></a><p></p>
<h1>Principal Display Panel - Bottle</h1>
<p class="First">NDC 18860-480-01</p>
<p>R<span class="Sub">x </span>Only<br><span class="Bold">ELESTRIN<span class="Sup">®</span></span></p>
<p>estradiol gel 0.06%</p>
<p><span class="Bold">FOR TOPICAL USE ONLY</span></p>
<p>Metered dose pump<br>container delivering<br>26 grams gel as<br>30 metered actuations.</p>
<p><span class="Bold">Gels are flammable.<br>Avoid fire, flame, or smoking<br>during application.</span></p>
<p><span class="Bold">AZUR PHARMA</span></p>
<div class="Figure">
<img alt="Principal Display Panel - Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e1a3641-25ca-41bd-a940-51ae0ec64ed9&amp;name=f3f8fca9-1981-471d-89f5-6b7fbb8f49d6-07.jpg"><p class="MultiMediaCaption">Bottle Label</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_f95d48e3-d4d2-43e3-b9bb-ea1d4114b5b9"></a><a name="section-16"></a><p></p>
<h1>Principal Display Panel - Carton</h1>
<p class="First">NDC 18860-480-60</p>
<p>R<span class="Sub">x </span>Only<br><span class="Bold">ELESTRIN<span class="Sup">®</span></span></p>
<p>estradiol gel 0.06%</p>
<p><span class="Bold">FOR TOPICAL USE ONLY</span></p>
<p>2 metered dose pump containers<br>each delivering 26 grams gel as<br>30 metered actuations.</p>
<p><span class="Bold">Attention pharmacist:<br></span>Dispense with enclosed<br>Patient Information leaflet.</p>
<p><span class="Bold">Important:<br></span>Read accompanying<br>directions carefully.</p>
<p><span class="Bold">AZUR PHARMA</span></p>
<div class="Figure">
<img alt="Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e1a3641-25ca-41bd-a940-51ae0ec64ed9&amp;name=f3f8fca9-1981-471d-89f5-6b7fbb8f49d6-08.jpg"><p class="MultiMediaCaption">Carton Label</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ELESTRIN 		
					</strong><br><span class="contentTableReg">estradiol gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:18860-480</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TRANSDERMAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">0.6 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIETHYLENE GLYCOL MONOETHYL ETHER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TROLAMINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:18860-480-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">35 g in 1 BOTTLE, PUMP</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:18860-480-60</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:18860-480-01</td>
<td class="formItem">35 g in 1 BOTTLE, PUMP</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021813</td>
<td class="formItem">06/01/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Jazz Pharmaceuticals Commercial Corp.
							(805611071)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f3f8fca9-1981-471d-89f5-6b7fbb8f49d6</div>
<div>Set id: 8e1a3641-25ca-41bd-a940-51ae0ec64ed9</div>
<div>Version: 6</div>
<div>Effective Time: 20120629</div>
</div>
</div> <div class="DistributorName">Jazz Pharmaceuticals Commercial Corp.</div></p>
</body></html>
